PULMONARY FUNCTION LAB · SPIROMETRY READY · TOPIC: COPD · REF: GOLD / ATS / FDA
The Pulmonary Function Lab Respiratory reference · U.S. edition
Pulmonology · Obstructive disease

COPD is progressive, but it is not inevitable. Smoking cessation changes the trajectory.

About 16 million American adults have been diagnosed with COPD, and millions more have the disease without knowing it. It is the fourth leading cause of death in the United States, and it is still — in 2025 — largely driven by a preventable cause. This is the practical map: what happens in the lungs, how it is staged, and how modern inhaled therapy changes the disease.

14 min read
GOLD/ATS-aligned
FEV1 · LABA/LAMA · ICS
16M
U.S. adults diagnosed with COPD — and millions more undiagnosed.
4th
Leading cause of death in the United States — and the only one still rising in some populations.
50%
Of adults with COPD are still working age — the impact on daily function is substantial.
75%
Of COPD deaths are attributed to smoking, occupational exposures, or air pollution — all modifiable.
Section 01 · The mechanism

Two overlapping diseases — emphysema and chronic bronchitis.

COPD is a diagnosis defined by persistent airflow obstruction that is not fully reversible — measured as a post-bronchodilator FEV1/FVC ratio below 0.70. It encompasses two classical phenotypes that frequently coexist in the same patient: emphysema, which affects the alveoli (air sacs), and chronic bronchitis, which affects the airways.

Emphysema is characterized by the destruction of alveolar walls, which reduces the surface area available for gas exchange and causes the small airways to collapse on exhalation. The lung loses its natural elastic recoil — which is why patients with emphysema develop hyperinflation (a barrel chest) and purse-lip breathing (a compensatory technique to maintain positive airway pressure). Destruction of the alveolar walls is driven primarily by neutrophilic inflammation, protease-antiprotease imbalance, and oxidative stress — all of which are accelerated by cigarette smoke.

Chronic bronchitis is defined clinically by chronic productive cough for at least three months per year for two consecutive years. It is driven by mucous gland hyperplasia, goblet cell metaplasia, and ciliary dysfunction — producing excessive mucus, impaired clearance, and chronic bacterial colonization of the airways. This phenotype is more responsive to bronchodilators but carries a higher rate of infectious exacerbations.

Alpha-1 antitrypsin deficiency is a rare but important genetic cause of emphysema, particularly in patients who develop COPD before age 45, have a strong family history, or have liver disease. It should be tested for once in every patient with COPD according to all major guidelines — and, if confirmed, qualifies the patient for augmentation therapy. For a broader picture of how chronic disease management is structured across conditions, a reference like this one on metformin for diabetes illustrates the same principles at work in a different disease.

Section 02 · Staging

The GOLD classification — spirometry-based staging of severity.

COPD severity is classified using the Global Initiative for Chronic Obstructive Lung Disease (GOLD) system, based on post-bronchodilator FEV1 as a percentage of predicted. GOLD staging should be combined with symptom burden (mMRC or CAT) and exacerbation history for a complete clinical picture.

GOLD stages 1–4
Based on post-bronchodilator FEV1
GOLD 1

Mild

FEV1 ≥ 80% predicted

Chronic symptoms may be mild or absent. Spirometry reveals obstruction even when the patient feels relatively well. Smoking cessation is the priority. Short-acting bronchodilators as needed.

GOLD 2

Moderate

FEV1 50–79% predicted

Dyspnea on exertion becomes more noticeable. Most patients in this stage benefit from a long-acting bronchodilator (LABA, LAMA, or both). Pulmonary rehabilitation should be considered.

GOLD 3

Severe

FEV1 30–49% predicted

Dyspnea on minimal activity, frequent exacerbations, reduced quality of life. Combination LABA/LAMA is standard. ICS may be added for frequent exacerbations or eosinophilia. Assess for oxygen therapy.

GOLD 4

Very severe

FEV1 < 30% predicted

Severe dyspnea at rest or with minimal activity, chronic respiratory failure possible. Triple therapy is common. Long-term oxygen therapy and consideration of lung transplantation or lung volume reduction for selected patients.

Section 03 · Symptoms

What patients notice — and what they too often dismiss as "just aging."

C

Chronic cough

Persistent cough, often productive. In chronic bronchitis it is present most days. Many smokers dismiss it as a normal "smoker's cough" — which delays diagnosis by years.

O

Ongoing sputum

Daily sputum production, especially in the morning. Changes in volume or color may indicate an exacerbation. Hemoptysis (blood in sputum) requires prompt evaluation.

L

Limitation of activity

Dyspnea with activities that used to be easy — stairs, walking uphill, carrying groceries. Patients often reduce activity to match their breathing, so the symptom is underreported unless specifically asked about.

D

Daily wheeze & tightness

Chest tightness or audible wheeze, especially on exertion or in cold air. Wheeze in a smoker over 40 is COPD until proven otherwise — but must also be distinguished from asthma and heart failure.

Section 04 · Inhaled therapy

The cornerstone of treatment — and why the device matters as much as the drug.

Inhaled therapy is the foundation of COPD management. The right medication in the wrong inhaler device — used incorrectly — delivers almost nothing to the lungs. Inhaler technique should be assessed at every visit, and the device chosen to match the patient's dexterity and inspiratory effort.

RESCUE · SABA / SAMA

Short-acting bronchodilators

Albuterol (SABA) and ipratropium (SAMA) provide rapid relief of acute breathlessness. Used as needed for symptom relief, not on a fixed schedule. Response is typically within 5 to 15 minutes and lasts 4 to 6 hours.

Patients who use rescue inhalers more than twice a week are inadequately controlled and should be on maintenance therapy. Frequent use is also a marker for exacerbation risk.

albuterol (ProAir, Ventolin, Proventil) · levalbuterol · ipratropium · combination albuterol/ipratropium
MAINTENANCE · LABA / LAMA

Long-acting bronchodilators

The mainstay of COPD therapy. LABAs (salmeterol, formoterol, olodaterol) and LAMAs (tiotropium, umeclidinium, aclidinium, glycopyrronium) relax airway smooth muscle for 12 to 24 hours. LAMAs are generally more effective than LABAs for COPD and are often first-line.

Combination LABA/LAMA inhalers are preferred for most patients with symptoms and reduce exacerbations more than either agent alone. Do not use LABA monotherapy in asthma — but in COPD, LABA monotherapy is acceptable if a LAMA is not tolerated.

tiotropium (Spiriva) · umeclidinium (Incruse) · salmeterol · formoterol · olodaterol · indacaterol · LABA/LAMA combinations (Anoro, Stiolto, Bevespi, Duaklir)
ADD-ON · ICS

Inhaled corticosteroids

ICS are not first-line in COPD and should not be used as monotherapy. They are added to LABA/LAMA for patients with frequent exacerbations (≥2 moderate or ≥1 severe per year), blood eosinophil counts above 300 cells/μL, or a history of asthma-COPD overlap.

Triple therapy (LABA/LAMA/ICS in one inhaler) reduces exacerbations and mortality in selected patients. Risks of ICS include pneumonia, oral candidiasis, and bruising — so the decision should be individualized.

fluticasone · budesonide · beclomethasone · triple combinations (Trelegy, Breztri)
ADJUNCT · NON-INHALED

Roflumilast & azithromycin

Roflumilast — an oral PDE4 inhibitor that reduces exacerbation frequency in patients with chronic bronchitis and severe COPD, particularly those with FEV1 < 50% and a history of exacerbations. GI side effects and weight loss limit tolerability.

Azithromycin — long-term low-dose azithromycin reduces exacerbations in selected patients at high risk. Requires attention to QT prolongation, hearing loss, and antimicrobial stewardship considerations.

roflumilast (Daliresp) · azithromycin 250 mg three times weekly
SUPPORTIVE · OXYGEN & VACCINES

Oxygen therapy & prevention

Long-term oxygen therapy improves survival in patients with chronic hypoxemia (PaO₂ ≤ 55 mmHg or SpO₂ ≤ 88% at rest). It does not improve survival in patients with only exercise-induced or nocturnal hypoxemia.

Vaccination is critical: influenza annually, pneumococcal (PCV20), COVID-19, RSV, and Tdap. Pulmonary rehabilitation improves exercise capacity and quality of life, and reduces hospitalizations. Smoking cessation is the single most effective intervention at any stage — it slows FEV1 decline more than any drug.

home oxygen · pulmonary rehab · smoking cessation · PCV20 · influenza · RSV · COVID-19
Section 05 · Exacerbations

Acute worsening — and why each one matters more than the last.

A COPD exacerbation is an acute worsening of dyspnea, cough, or sputum that requires additional treatment. Exacerbations accelerate lung function decline, reduce quality of life, and increase mortality. Preventing them is one of the main goals of maintenance therapy.

Exacerbation timeline · typical course
Day 0 to week 4
Day 0–1 · Onset
Warning signs

Increased breathlessness, more frequent cough, change in sputum volume or color. Acting on day 1 with rescue inhaler and contacting the clinician can prevent hospitalization.

Day 1–3 · Peak
Treatment initiation

Short-acting bronchodilators, systemic corticosteroids (usually prednisone 40 mg × 5 days), and antibiotics if the patient has increased sputum purulence plus another cardinal symptom. Antibiotics are not always appropriate — sputum color alone is a weak signal.

Day 3–7 · Hospitalization risk
When to seek emergency care

Worsening dyspnea despite treatment, confusion, inability to speak in full sentences, use of accessory muscles, or SpO₂ below 88%. Non-invasive ventilation (BiPAP) reduces mortality in hypercapnic respiratory failure during severe exacerbations.

Week 2–4 · Recovery
Post-exacerbation

Recovery is slow — often weeks. Reassess inhaler technique and maintenance therapy. Exacerbations are a trigger to review whether the patient needs escalation of maintenance treatment or oxygen assessment.

Section 06 · Safety and inhaler technique

Common problems with inhalers — and how to fix them.

INHALER · SAFETY

Up to 90% of patients use their inhaler incorrectly. Poor technique means poor drug delivery — no matter how good the medication.

Shake before use

Metered-dose inhalers (MDIs) must be shaken vigorously for 5 seconds before each use — otherwise the propellant and medication separate and the patient receives mostly propellant.

Use a spacer

A spacer (valved holding chamber) dramatically improves lung delivery with MDIs — especially for older adults and anyone with poor hand-breath coordination. It is not optional for many patients.

Slow, deep inhalation

With an MDI, inhale slowly and deeply over 3 to 5 seconds. With a dry powder inhaler (DPI), inhale quickly and forcefully. The correct technique is the opposite for the two device types — patients often confuse them.

Rinse after ICS

After using an inhaled corticosteroid, rinse the mouth and spit out the water to prevent oral thrush (candidiasis) and hoarseness. This is one of the most commonly skipped steps.

Check the dose counter

Most modern inhalers have dose counters. Do not use past the counter's zero mark — the remaining puffs may not deliver adequate medication. Do not float inhalers in water — that old technique is unreliable.

Reassess at every visit

Inhaler technique should be observed and corrected at every clinical encounter — not just at initiation. Even experienced patients can develop bad habits over time.

Section 07 · What to watch for

Signs that require urgent medical evaluation.

Urgent evaluation

If any of these appear in a patient with COPD, seek immediate medical attention.

Severe breathlessness at rest that does not improve with rescue inhaler. Possible severe exacerbation or respiratory failure — requires emergency evaluation.
Confusion, drowsiness, or slurred speech. Possible hypercapnic encephalopathy from CO₂ retention — a medical emergency requiring non-invasive ventilation or intubation.
Inability to speak in full sentences, or use of accessory muscles. Signs of respiratory distress requiring immediate intervention.
Oxygen saturation below 88% on room air. Possible acute hypoxemic respiratory failure — requires urgent evaluation. Do not delay while adjusting home oxygen without medical guidance.
Chest pain, especially with breathlessness or palpitations. Could indicate pneumothorax (especially with emphysema), pulmonary embolism, or cardiac ischemia — all emergencies.
Fever with worsening cough and purulent sputum. Possible pneumonia, which is more serious in COPD. Requires prompt evaluation and imaging.
Coughing up blood (hemoptysis). Requires prompt evaluation — could indicate infection, bronchiectasis, or malignancy.
New or worsening leg swelling with breathlessness. Possible cor pulmonale (right heart failure from chronic lung disease) — requires evaluation.
Section 08 · Access & affordability

COPD medications are widely covered — but inhaler pricing varies dramatically.

Inhalers in the U.S. are priced very differently from one another. Brand-name maintenance inhalers can cost $300 to $600 per month without insurance, and many patients hit coverage barriers. A 2022 law capped insulin at $35/month for Medicare patients but no equivalent exists for inhalers. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D has improved the situation substantially for Medicare patients, but commercial insurance varies by plan. Manufacturer copay cards and patient assistance programs help substantially — every major inhaler brand has one, and clinic staff can help enroll patients.

Generics have gradually entered the market. Albuterol (rescue) is available as a low-cost generic. Some maintenance inhalers now have authorized generics, and pricing pressure continues. Patients should always ask the pharmacist whether a generic or alternative inhaler in the same class is available at a lower cost.

For patients on multiple chronic medications — which is common in COPD, given the frequent coexistence of hypertension, diabetes, and cardiovascular disease — checking pharmacy-level pricing is worth the time. The same medication can cost several times more at one licensed pharmacy than another. If you would like to see what transparent online seller selection looks like, you can review the standards used to select pharmacies through contact Metformin4You, and the step-by-step ordering process is documented in this how to order Metformin online guide.

Before filling from any seller — online or local — verify them. A working VIPPS seal that resolves to a live NABP record, a real U.S. street address, and a prescription requirement that cannot be waived. Inhalers are critical respiratory medications — using a pharmacy you cannot hold accountable is not worth the risk.

Section 09 · Questions

Five asked most often in the pulmonary clinic.

Q·01 What is COPD? +
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by persistent airflow limitation that is not fully reversible. It includes two overlapping conditions: emphysema (destruction of alveolar walls) and chronic bronchitis (chronic productive cough). In the U.S., cigarette smoking is the dominant cause, though occupational exposures, air pollution, and genetic factors (including alpha-1 antitrypsin deficiency) also contribute.
Q·02 How is COPD diagnosed? +
COPD is confirmed with spirometry — a pulmonary function test that measures how much air a person can exhale forcefully in one second (FEV1) and the total amount exhaled (FVC). A post-bronchodilator FEV1/FVC ratio below 0.70 confirms airflow obstruction. Severity is graded by FEV1 as a percent of predicted: GOLD 1 (≥80%), GOLD 2 (50–79%), GOLD 3 (30–49%), or GOLD 4 (<30%).
Q·03 What inhalers are used for COPD? +
Inhaled therapy is the cornerstone of COPD management. Short-acting bronchodilators (albuterol, ipratropium) are used as rescue medications. Long-acting bronchodilators — LABAs (salmeterol, formoterol) and LAMAs (tiotropium, umeclidinium) — are the mainstay of daily maintenance. Combination LABA/LAMA inhalers are preferred for most patients with symptoms. Inhaled corticosteroids (ICS) are added for patients with frequent exacerbations or high eosinophil counts.
Q·04 What is a COPD exacerbation? +
A COPD exacerbation is an acute worsening of respiratory symptoms — increased breathlessness, cough, and sputum production or change in sputum color — that requires additional treatment. Exacerbations accelerate lung function decline, reduce quality of life, and increase mortality. Treatment typically includes short-acting bronchodilators, systemic corticosteroids, antibiotics when indicated, and sometimes hospitalization.
Q·05 Can COPD be reversed or cured? +
There is no cure for COPD, and the structural lung damage is not reversible. However, smoking cessation is the single most important intervention — it slows the rate of lung function decline substantially. Inhaled bronchodilators improve symptoms and reduce exacerbations. Pulmonary rehabilitation improves exercise capacity and quality of life. Oxygen therapy improves survival in patients with chronic hypoxemia. Lung volume reduction and transplantation are options for selected patients. For a useful comparison of how another chronic medication is priced across pharmacies, this reference on Metformin online pharmacy illustrates the same dynamics that apply to inhalers.
◆ Sources & Verification
This reference is aligned with public clinical guidance from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025 Report, the American Thoracic Society (ATS), the National Heart, Lung, and Blood Institute (NIH), and the FDA-approved prescribing information for tiotropium and Trelegy Ellipta (triple therapy). Drug-label information draws on the National Library of Medicine's DailyMed database and MedlinePlus. Pharmacy verification follows the NABP VIPPS program.
◆ Before the next refill

COPD is manageable. Prescription pricing should not be the obstacle.

Inhaler prices vary more than almost any other prescription category — and the same pharmacy-level spread applies to every chronic medication. A short comparison across licensed U.S. sellers before each refill is a useful habit to build, and it is the same approach that resources like Metformin4You use to help patients see the current range for a widely prescribed generic.

Open the price comparison